• About us
  • Privacy Policy
  • Contact us
Neo Science Hub
ADVERTISEMENT
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
Neo Science Hub
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

“No major shift in business environment in US”

Rashmi NSH by Rashmi NSH
2 years ago
in Pharmaceutical & Chemical, Science News
0
G-V-Prasad

In light of the U.S. pharmaceutical market’s evolving landscape under President Trump’s administration, we sought insights from GV Prasad, Co-Chairman and Managing Director of Dr. Reddy’s Laboratories. Addressing the anticipated impacts of U.S. trade policy changes and the strategic adjustments necessitated by global trade dynamics, Prasad provides a nuanced view of the challenges and opportunities ahead for Indian pharmaceutical companies. His responses underscore the competitive nature of the U.S. generics market and highlight strategic moves to enhance supply chain resilience in response to shifting sentiments towards key suppliers like China.

With Donald Trump taking office and the potential for significant changes in U.S. trade policies, how do you anticipate these changes will impact the Indian pharmaceutical industry, particularly in terms of market access and regulatory challenges for exporting generics to the U.S.?

I do not see any major shift in the business environment for Indian pharmaceutical companies in the USA.  The generics market in the USA is already highly competitive and hence tariffs and localization initiatives are unlikely to make a measurable impact on competition.  Since India is primarily in generics with very limited presence in innovation, I do not foresee any major impacts from policy changes under the Trump administration.

G-V-Prasad

Read more about
G V Prasad

Considering the Trump administration’s focus on reshaping global trade dynamics, especially with key suppliers like China, what strategic adjustments is your company considering to mitigate risks and capitalize on potential trade shifts? How do you plan to enhance your supply chain resilience to maintain a steady supply of APIs and finished products to the U.S. market?

Indian CDMO’s and CRO’s are already seeing increasing traction for their business from USA as a result of the Biosecure act. While the act itself did not pass the senate, the negative US sentiment towards China is driving more opportunities to India. However China has made giant strides in innovation and has emerged as a leading biopharmaceutical innovator and this is going to power their global growth aided by favourable government support and a vibrant local market. Already China ranks second in terms of innovation next only to the USA.

We continue to have a global supply chain with increasing reliance on local Indian producers and vertical integration. We also believe China will remain a major supplier of key materials and we will need to be interdependent on each other. China will remain a major supplier and our own exports to China will also increase. We do not see any major shift in the near term but we will watch how the policies evolve.

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Telegram (Opens in new window) Telegram
  • Email a link to a friend (Opens in new window) Email
Tags: featuredGV Prasad (DRL)pharmaPharma Bizsciencenews
Rashmi NSH

Rashmi NSH

Other Posts

Bar chart of decreasing bars beside a line-art antibiotic icon

When the Last Antibiotic Fails: ICMR Finds 91 Per Cent Carbapenem Resistance in a Common Hospital Pathogen

November 21, 2026
0
Map of India's east coast with a stylised cyclone and its forecast track

Akvan Turns North and Drops a Category: IMD Now Expects a Severe Cyclone Between Narsapur and Puri, While Andhra’s Own Forecasters Expect Less

November 21, 2026
0

Antalya’s Last Forty-Eight Hours: Two Contradictory Paragraphs on Fossil Fuels, and India’s Line on the Carbon Budget

Disarm, Don’t Kill: CCMB Scientists Find Two Compounds That Stop a Deadly Fungus Turning Invasive

Eighty Per Cent of the Cost: Andhra Pradesh Raises the Stakes in India’s Chip-Subsidy Contest

Before the First Breath: UNEP and WHO Say Hormone-Disrupting Chemicals Reach Us in the Womb

The Morning Eye Closes: NASA Will Switch Off Terra After 27 Years of Watching the Planet

A Status Lost: Measles Is Endemic Again in the United States, Mexico and Bolivia

Next Post
Spine

Transforming Spine Care with Precision & Innovation

Subscribe to Us

Latest Articles

Cross-section of a human eye with the optic nerve head highlighted

FDA Orders Eye-Risk Warnings on All GLP-1 Drugs, From Ozempic to Mounjaro

November 12, 2026
11

Delhi’s Diwali, Measured: Firecrackers Drove 71% of Fine Particles, Lead Hit 20 Times the Limit, and the Worst Readings Went Missing

Global Carbon Budget 2026: The World’s Fossil Emissions Dip, India’s Rise 4.4%, and the 1.5 °C Budget Is Nearly Spent

A New Kind of Blood Thinner: FDA Approves Asundexian to Prevent Repeat Strokes

Andhra Pradesh Opens the Door to Small Nuclear Reactors, Robots and Giga-Scale AI Data Centres — With the Details Still to Come

“Off the Charts”: WMO Tells COP31 That 2026 Is Among the Hottest Years on Record as a Record El Niño Builds

  • Advertise
  • Terms and Conditions
  • Privacy Policy
  • Refund Policy
  • Contact
For Feedback : Email Us

Copyrights © 2025 Neo Science Hub

No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Copyrights © 2025 Neo Science Hub

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist